Suppr超能文献

近视儿童中使用 0.01%阿托品、角膜塑形镜或联合治疗后, 中心凹下脉络膜厚度的变化。

Changes in subfoveal choroidal thickness in myopic children with 0.01% atropine, orthokeratology, or their combination.

机构信息

Department of Ophthalmology, The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Shahekou District, Dalian, China.

出版信息

Int Ophthalmol. 2021 Sep;41(9):2963-2971. doi: 10.1007/s10792-021-01855-5. Epub 2021 May 5.

Abstract

PURPOSE

To compare the changes in subfoveal choroidal thickness (SFChT) in myopic children treated with 0.01% atropine, orthokeratology (OK), or their combination in myopic children, and to study the connection between increase in SFChT and axial length (AL) elongation.

METHODS

This is a prospective, randomized, controlled study. A total of 67 children were included; 22 patients were randomly assigned to the SA group (patients with spectacles and 0.01% atropine), 24 patients were randomly assigned to the OK group (OK), and 21 patients were randomly assigned to the OKA group (OK and 0.01% atropine). Comprehensive ophthalmologic examinations were performed at baseline, 1 month, 6 months, and 12 months.

RESULTS

After 1 month, SFChT increased by 5.41 ± 1.65 μm in the SA group, 17.46 ± 2.79 μm in the OK group, and 20.19 ± 2.18 μm in the OKA group (P = 0.00), whereas AL was not significantly increased. After 12 months, the changes of SFChT were not increased significantly compared with that at 1 month; AL increased by 0.20 ± 0.03 mm in the SA group, 0.28 ± 0.03 mm in the OK group, and 0.14 ± 0.03 mm in the OKA group (P = 0.00). The change in SFChT at 12 month was negatively correlated with the change in AL at 12 months.

CONCLUSION

The control of AL elongation was better in SA group than OK group. The increase in SFChT was best in OKA group, followed by OK group, and the changes were significant after only 1 month. In addition, the increase in SFChT may influence AL elongation and myopia progression.

摘要

目的

比较 0.01%阿托品、角膜塑形术(orthokeratology,OK)或两者联合治疗近视儿童的眼底部脉络膜厚度(subfoveal choroidal thickness,SFChT)的变化,并研究 SFChT 增加与眼轴(axial length,AL)伸长之间的关系。

方法

这是一项前瞻性、随机、对照研究。共纳入 67 例儿童,22 例患者随机分为 SA 组(戴眼镜和 0.01%阿托品),24 例患者随机分为 OK 组(OK),21 例患者随机分为 OKA 组(OK 和 0.01%阿托品)。在基线、1 个月、6 个月和 12 个月时进行全面眼科检查。

结果

1 个月后,SA 组 SFChT 增加 5.41±1.65μm,OK 组增加 17.46±2.79μm,OKA 组增加 20.19±2.18μm(P=0.00),而 AL 无明显增加。12 个月后,SFChT 的变化与 1 个月时相比无明显增加;SA 组 AL 增加 0.20±0.03mm,OK 组增加 0.28±0.03mm,OKA 组增加 0.14±0.03mm(P=0.00)。12 个月时 SFChT 的变化与 12 个月时 AL 的变化呈负相关。

结论

与 OK 组相比,SA 组控制 AL 伸长更好。OKA 组 SFChT 增加最好,其次是 OK 组,仅 1 个月后变化明显。此外,SFChT 的增加可能会影响 AL 伸长和近视进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b26e/8364521/4d3b53d78e4c/10792_2021_1855_Fig1_HTML.jpg

相似文献

1
Changes in subfoveal choroidal thickness in myopic children with 0.01% atropine, orthokeratology, or their combination.
Int Ophthalmol. 2021 Sep;41(9):2963-2971. doi: 10.1007/s10792-021-01855-5. Epub 2021 May 5.
2
Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness.
Cont Lens Anterior Eye. 2021 Jun;44(3):101348. doi: 10.1016/j.clae.2020.06.006. Epub 2020 Jun 30.
4
Choroidal thickness and axial length changes in myopic children treated with orthokeratology.
Cont Lens Anterior Eye. 2017 Dec;40(6):417-423. doi: 10.1016/j.clae.2017.09.010. Epub 2017 Sep 19.
5
Orthokeratology and Low-Intensity Laser Therapy for Slowing the Progression of Myopia in Children.
Biomed Res Int. 2021 Jan 27;2021:8915867. doi: 10.1155/2021/8915867. eCollection 2021.
6
Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children.
Int Ophthalmol. 2021 Mar;41(3):1011-1017. doi: 10.1007/s10792-020-01658-0. Epub 2020 Nov 17.
9
Comparison of the Clinical Efficacies of 0.01% Atropine and Orthokeratology in Controlling the Progression of Myopia in Children.
Ophthalmic Epidemiol. 2021 Oct;28(5):376-382. doi: 10.1080/09286586.2021.1875010. Epub 2021 Jan 20.
10
Pattern of Axial Length Growth in Children Myopic Anisometropes with Orthokeratology Treatment.
Curr Eye Res. 2020 Jul;45(7):834-838. doi: 10.1080/02713683.2019.1701685. Epub 2019 Dec 17.

引用本文的文献

2
Repeatability, reproducibility, and agreement for three optical coherence tomography instruments.
BMC Ophthalmol. 2025 Jul 28;25(1):427. doi: 10.1186/s12886-025-04257-8.
5
How Have Animal Models Increased our Understanding of Human Myopia?
Invest Ophthalmol Vis Sci. 2025 Jun 5;66(7):2. doi: 10.1167/iovs.66.7.2.
6
Childhood Myopia Part I: Contemporary Treatment Options.
Invest Ophthalmol Vis Sci. 2025 Jun 5;66(7):6. doi: 10.1167/iovs.66.7.6.
7
Effects of atropine on choroidal thickness in myopic children: a meta-analysis.
Front Pharmacol. 2024 Oct 21;15:1440180. doi: 10.3389/fphar.2024.1440180. eCollection 2024.

本文引用的文献

1
Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness.
Cont Lens Anterior Eye. 2021 Jun;44(3):101348. doi: 10.1016/j.clae.2020.06.006. Epub 2020 Jun 30.
2
Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
Ophthalmology. 2020 Dec;127(12):1603-1611. doi: 10.1016/j.ophtha.2020.06.004. Epub 2020 Jun 7.
3
Overnight orthokeratology.
Cont Lens Anterior Eye. 2020 Aug;43(4):322-332. doi: 10.1016/j.clae.2020.03.018. Epub 2020 Apr 22.
4
Short-Term Effect of Low-Dose Atropine and Hyperopic Defocus on Choroidal Thickness and Axial Length in Young Myopic Adults.
J Ophthalmol. 2019 Aug 21;2019:4782536. doi: 10.1155/2019/4782536. eCollection 2019.
5
A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control.
Optom Vis Sci. 2019 Aug;96(8):556-567. doi: 10.1097/OPX.0000000000001410.
6
Combined Atropine with Orthokeratology for Myopia Control: Study Design and Preliminary Results.
Curr Eye Res. 2019 Jun;44(6):671-678. doi: 10.1080/02713683.2019.1568501. Epub 2019 Jan 24.
7
Effects of time-of-day on inhibition of lens-induced myopia by quinpirole, pirenzepine and atropine in chicks.
Exp Eye Res. 2019 Apr;181:5-14. doi: 10.1016/j.exer.2019.01.008. Epub 2019 Jan 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验